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Abstract
Background: Douchi (fermented Glycine max Merr.) is produced from fermented soybeans, which is widely used in
traditional herbal medicine. In this study, we investigated whether Douchi attenuates protein kinase C (PKC) and
interleukin (IL)-4 response and cutaneous inflammation in Atopic dermatitis (AD)-like NC/Nga mice.
Methods: To induce AD-like skin lesions, D. farinae antigen was applied to the dorsal skin of
3-week-old NC/Nga mice. After inducing AD, Douchi extract was administered 20 mg/kg daily for 3 weeks to the
Douchi-treated mice group. We identified the changes of skin barrier and Th2 differentiation through PKC and IL-4
by immunohistochemistry.
Results: Douchi treatment of NC/Nga mice significantly reduced clinical scores (p < 0.01) and histological features.
The levels of PKC and IL-4 were significantly reduced in the Douchi-treated group (p < 0.01). The reduction of IL-4
and PKC led to decrease of inflammatory factors such as substance P, inducible nitric oxide synthase (iNOS) and
Matrix metallopeptidase 9 (MMP-9) (all p < 0.01). Douchi also down-regulated Th1 markers (IL-12, TNF-α) as well as
Th2 markers (IL-4, p-IκB) (p < 0.01).
Conclusion: Douchi alleviates AD-like skin lesions through suppressing of PKC and IL-4. These results also lead to
diminish levels of substance P, iNOS and MMP-9 in skin lesions. Therefore, Douchi may have potential applications
for the prevention and treatment of AD.
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Background
Atopic dermatitis (AD) is a chronic inflammatory skin
disease with a complex etiology encompassing immuno-
logic response [1]. Various factors including genetic,
environmental, and immunological disruption contribute
to skin barrier dysfunction [1]. AD can induce an atopic
march, which is a complex process involving sinusitis,
allergic rhinitis and asthma. Thus, early treatment is
necessary for patients with AD [2].
One of the main feature of AD is known to imbalance
of Th1/Th2 immune response through the induction of
T helper (Th) 2 cytokines such as interleukin (IL)-4 in
skin lesions [3]. Recently, several studies have reported
that Th2 cytokine activity could control the onset of AD
in animal models [4, 5]. Activated Th2 cells secret IL-4,
IL-5 and IL-13; IL-4, in particular, has been demon-
strated to enhance AD through the promotion of T cell
differentiation [6]. IL-4 stimulates the degranulation of
mast cells, the release of substance P (which is related to
itching) [7], MMP-9 (which induces edema) [8], and
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iNOS (which is related to angiogenesis) [9]; thereby
amplifying inflammatory skin damage [10].
Another primary event in the pathogenesis of AD is the
dysfunction of lipid enriched extra-cellular matrix includ-
ing ceramide in the stratum corneum [11]. The damage of
lipid barrier is induced by activation of protein kinase C
(PKC), which plays a role as the elicitation of AD [12]. In
addition, PKC is crucial for Th2 cytokine activation, which
shifts Th1/2 balance to Th2-dominant state, resulting in
an acute inflammatory state [13]. Furthermore, this state
activates mast cell, which leads to release various inflam-
matory mediators. This entire process plays a key role in
the initiation of AD. Therefore, the suppression of Th2 cy-
tokines by blocking PKC activation is a novel strategy for
protecting against AD [14].
With Conventional medicine, AD occurs due to a com-
plicated set of factors. It is characterized by skin barrier
dysfunction and the disruption of the immune system in-
volving the network of Th2 cytokines [1]. AD occurs in
23.6 % of infants less than 24 months old in Korea [12].
As a previous study, infants are characterized by Th2-
dominant state, therefore when they are exposed to exter-
nal antigens, infants are more likely to get AD [15]. At
present, the typical treatments available are dominated by
the corticosteroid medication which has an effect of
suppressing Th2 cytokines. However, these steroids can
cause adverse effects including a risk of fracture, atropho-
derma, and growth delay. Therefore, the development of
natural remedies is highly desirable [16].
Within traditional medicine, inflammatory disease is
commonly diagnosed as heat syndrome [17]. Heat syn-
drome (Zheng) is a basic concept in CAM, which may
can be represented as symptoms like erythema, flushed
face, high fever, red tongue and so on [18]. Heat
syndrome is one of major signs of AD in CAM [17], and
generally corresponds to inflammation and infection in
neuro-endocrine immune system of western medicine
[19]. Therefore, CAM treats AD with ‘heat-clearing’
medicines to reduce accumulated heat in skin [20].
Douchi (fermented Glycine max Merr.) is a kind of
fermented soybean and a representative herbal medicine
for reducing ‘heat’ in traditional medicine [21]. Douchi
is used as a complementary and alternative medicine in
the treatment of heat-related disease such as heartburn,
inflammation and common cold [21]. It was found that
it contains isoflavones such as genistein, daidzein [22],
and its components are known to have an effect of regu-
lating PKC and Th2 response in inflammatory disorders
[23–25]. Several animal studies also reported that fermen-
ted soybeans, which is similar to Douchi, have therapeutic
effects on inflammatory allergic diseases that involve Th2
immunomodulatory activity [26, 27]. As a type of fermen-
ted soybean, Douchi also could be expected to have simi-
lar effect in inflammation response such as AD.
Inflammation response is closely related to oxidative
stress and lipid metabolism [28]. As previous in vitro
studies, Douchi is known to have anti-oxidative effect
and anti-lipid peroxidative effect [29, 30]. Inducible ni-
tric oxide synthase (iNOS) is common essential players
of inflammation response and oxidative stress [31],
in addition, activation of lipid metabolism increased
inflammation reactions by producing pro-inflammatory
cytokines [28]. Therefore, the antioxidant and anti-lipid
peroxidative property of Douchi implied that it might
have possibility of inhibiting inflammation response.
However, the role of Douchi on inflammatory disease in
skin has not been studied yet.
Thus, based on the known effect of Douchi, we
explored to determine whether Douchi alleviates clinical
AD symptoms through regulating further expanding
inflammatory factors including mast cells, substance P,
iNOS and MMP-9 as well as PKC and IL-4. Moreover,
we also measured Th1 and Th2 differentiation through
checking IL-12, TNF-α (Th1 markers) versus IL-4, p-IκB
(Th2 markers) to identify Th1/Th2 imbalance.
Methods
Preparation of Douchi extract
The Douchi used in this study was purchased from
Namyoung Pham (Muju, Korea). The procedure used to
manufacture Douchi was as follows: first, black soybeans
were fermented in Artemisia Apiacea Herba and Mori
Folium extracts (1: 1) for 5 days at 37–38 °C; next, 100 g
of fermented soybeans were decocted with 1000 mL of
distilled water for 3 h and then filtered; after concentrat-
ing this mixture to 50 mL under reduced pressure using
a rotary evaporator, the filtrate was freeze-dried. We
obtained 14.74 g of the extract (yield: 14.74 %) for use.
Fingerprinting analysis of Douchi extract with high-
performance liquid chromatography (HPLC)
HPLC-based fingerprinting was performed using the
Agilent technologies 1200 series (Agilent Technologies,
CA, USA), a binary solvent delivery pump (G1312A), a
vacuum degasser (G1322A), an auto-sampler (G1329A),
a diode array detector (G1315D) with detection at
260 nm, thermostate column compartment (G1316A)
maintained at 35 °C and AgilentChem Station software.
For analytical scale study, concentrations of standard
samples and plant extracts were injected (15 μL) onto a
AegisPak-LC18 column (4.6 × 150 mm; pore size, 3 μm).
The mobile phases were solvent A [0.1 % formic acid
aqueous (v/v)] and solvent B (acetonitrile) at a flow rate
of 0.5 mL/min. The gradient flow was as follows:
initiation-5 % B, 20 min-20 % B, 28 min-30 % B, 32 min-
60 % B, 37 min-60 % B, 40 min-5 % B. A standard
solution, containing daidzin (1), daidzein (2), genistin (3)
and genistein (Sigma-Aldrich, St. Louis, MO, USA), was
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prepared by dissolving in distilled water (10 mg/
100 mL). The solution was filtered through a 0.45 μm
membrane filter and HPLC was performed. The concen-
trations of four compounds in the exact were calculated
with reference to standard curve of the corresponding
compound.
As shown in Fig. 1, daidzin (1), daidzein (2), genistin
(3) and genistein (4) were the major compounds of
Douchi and raw soybean extract, which detected
amounts of 1178.0, 170.9, 2027.5 and 265.3 μg/mL of
the Douchi extract, respectively. In raw soybean samples,
the amount of individual isoflavones was found to be
706.4, 24.8, 937.9 and 29.2 μg/mL (Table 1). As antici-
pated, the overall chemical content in raw soybean was
significantly lower than that in Douchi. It was no doubt
that the proportion of genistin (2027.5 μg/mL) was high-
est in Douchi extract.
Animal and AD induction
Male 3-week-old NC/Nga mice (13–15 g each) were
obtained from Central Lab Animal Inc. (Seoul, Korea)
and maintained in an air-conditioned animal room for
2 weeks before the experiments began. The mice were
divided into three groups (n = 10 per group) as follows:
1) Ctrl group, which was not induced AD and were
given water, 2) AD group, which induced AD and were
given water 3) DT group, which Douchi-treated AD-in-
duced mice.
In our experiment, the method used for induction of
AD-like skin lesions was depends on previous studies
[32–35]. It is as followings. For barrier dysruption, the
back regions of the mice was stripped, and 1 mL of 5 %
sodium dodecyl sulfate (SDS) (Sigma-Aldrich, St. Louis,
MO, USA) was rubbed on the back of each mouse 20
times using a cotton swab to remove the lipid lamella of
Fig. 1 HPLC-DAD analysis of the exacted Douchi (fermented Glycine max Merr.). Raw soy bean (Normal) and Douchi (Fermented soybean)
analyzed by HPLC. Peak number : daidzin (1), daidzein (2), genistin (3) and genistein (4) at 260 nm
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the stratum corneum. Dermatophagoides (D.) farinae
crude extract (100 mg, Biostir Inc., Kobe, Hyogo, Japan)
was applied 6 times per week for 3 weeks.
Mice in DT group were orally administered Douchi ex-
tract 20 mg/kg for 3 weeks daily. Animals were sacri-
ficed 72 h after the last Douchi administration, and
histological specimens were collected. All procedures
involving animals were approved by the Institutional
Animal Care and Use Committee of Pusan National
University (IACUC number: PNU-2014-0732). We
followed the NIH Guide for the Care and Use of
Laboratory Animals throughout this study. All data were
evaluated by observers who were blinded to the experi-
mental conditions.
Evaluation of skin dermatitis severity
The severity of morphology in the dorsal skin was evalu-
ated after 3 weeks and compared to the baseline. The
items of skin score are (1) erythema/hemorrhage (2)
scarring/dryness (3) edema (4) excoriation/erosion was
scored as 0 (none), 1 (mild), 2 (moderate), or 3 (severe).
The sum of the individual scores was defined as the
atopy skin score [36].
Histochemistry
Sodium pentobarbital was used to sedate mice. Anesthe-
tized mice were fixed in 10 % neutral buffered formalin
(NBF) solution, and a vascular rinse was performed for
24 h at room temperature. Fixed dorsal tissue slices were
embedded in paraffin. After embedding, 5 μm thick
sections were histochemically stained.
To investigate general morphology, we performed
hematoxylin and Eosin staining. To investigate capillary’s
changes such as size and braches, we performed Phloxine-
tartrazine staining. To investigate edema changes such as
collagen fiber distribution, we performed Masson’s tri-
chrome staining. To investigate the distribution and mor-
phological changes of the mast cells, we performed
histochemical staining with Luna’s staining. To investigate
the lipid lamella in epithelium, we performed histochem-
ical staining with sudan black B after the samples were
prepared according to routine historical procedures for
cryo-section.
Immunohistochemistry
Dorsal skin slices were steeped in proteinase K solution
(20 μg/mL) to undergo proteolysis for 5 min. The
proteolysed slices were incubated in blocking serum
(10 % normal goat serum) for 2 h. Then, the slices were
incubated with goat anti-PKC (1:100, Santa Cruz
Biotechnology, Inc., Dallas, TX, USA), goat anti-IL4
(1:100, Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), goat anti-IL12B (1:100, Santa Cruz Biotechnology,
Inc., Dallas, TX, USA), goat anti-p-IκB (1:500, Santa
Cruz Biotechnology, Inc., Dallas, TX, USA), goat anti-
TNF-α (1:200, Santa Cruz Biotechnology, Inc., Dallas,
TX, USA), goat anti-substance P (1:100, Santa Cruz
Biotechnology, Inc., Dallas, TX, USA), goat anti-MMP-9
(1:100, Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), goat anti-iNOS (1:100, Santa Cruz Biotechnology,
Inc., Dallas, TX, USA), all of which are primary anti-
bodies, for 72 h in a 4 °C humidified chamber. Next, the
slices were linked with biotinylated rabbit anti-goat IgG
(1:100, Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), which is a secondary antibody, for 24 h at room
temperature. After the slices were exposed to the sec-
ondary antibody, an avidin-biotin complex kit (Vector
Laboratories, Inc., Burlingame, CA, USA) was applied
for 1 h at room temperature. Finally, slices were devel-
oped with 0.05 M tris-HCl buffer solution (pH 7.4),
which consists of 0.05 % 3,3’-diaminobenzidine and
0.01 % HCl, and then counter-stained with hematoxylin.
We observed skin damage such as elimination of the
stratum corneum, epithelial cell hyperplasia, increased
infiltration of granular leukocytes and lymphocytes into
the basal layer, increased capillary distribution, and
increased edema in the dermis. In contrast, the DT group
exhibited less skin damage in most regions (Fig. 2).
Image analysis and statistical analysis
To produce numerical data from our immunohisto-
chemical results, an image analysis was performed using
Image Pro Plus (Media Cybernetics, Rockville, MD,
USA). Data were presented as the means ± standard
error and were evaluated with one-way Analysis of
Variance (ANOVA) followed by Duncan’s multiple
comparison test among different groups, if needed. The
statistical significances of the differences were analyzed
with SPSS software (PASW Statistics 18.0, IBM,
Armonk, NY, USA) with a significance level of p < 0.01.
Results
Alleviating effect of skin damage
Change of skin features
The repeated application of D.farinae crude extract wors-
ened AD-like skin scores and symptoms of hemorrhage,
edema, scarring, dryness and erosion. Administering
Douchi was observed to alleviate skin damage. The atopy
skin score was evaluated 7.8 ± 0.3 in the AD group, 4.1 ±
0.4 in the DT group. Significant differences were shown
between all of the groups (p < 0.01). In the DT group,
Table 1 Contents of isoflavones from extracts by HPLC-DAD
Sample ID Contents of isoflavones (μg/mL)
daidzin daidzein genistin genistein
Raw soybean 706.41 24.88 937.94 29.19
Douchi 1178.05 170.90 2027.54 265.33
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clinical scores and symptoms were significantly reduced
as compared to AD group (p < 0.01) (Fig. 2).
To observe changes in capillaries, we created incisions
and pushed aside the skin. Capillaries were photographed
with 4× magnification and observed after inversion. In the
DT group, the size and number of capillary branches
decreased by 38 % compared to the AD group (Fig. 2).
Regulation of Th2 differentiation
Repair of Lipid barrier
Intercellular spaces of epidermal stratum corneum
contain extensive arrays lipid lamella, which is mainly
composed of ceramide [37]. Ceramide deficiency
induced PKC production, that leads to AD-like skin
lesion [37].
We identified that layers of lamella were more disap-
peared in AD group compared with DT group (Fig. 3).
The result of Sudan black B staining indicated that the
thicker layers of lipid lamella appeared in epidermis of
DT group compared with AD group.
Amelioration of PKC activity
In the AD group, PKC was activated by ceramide defi-
ciency in stratum corneum by exposure to SDS and
D.farinae. Immunohistochemical staining with anti-PKC
antibodies indicated that a PKC-positive reaction
Fig. 2 The mitigative effect of Douchi treatment for AD symptoms. The skin features demonstrated visually a marked reduction in DT compared
with AD. Incision of red box is analyzed to identify capillary distribution. In our image analysis of the capillaries, the size and branch of capillary
increased in the AD, but decreased in the DT (4×). In H&E result, red spot indicates capillary, ↕: hyperplasia of the epithelium. *: p < 0.01 compared
with AD, #: p < 0.01 compared with Ctrl. Bar size: 200 μm (Figure in H&E). Abbreviations; AD: AD-induced mice, Ctrl: non treatment mice, DT: Douchi
extract-treated mice after AD inducement, Der: dermis, Epi: epidermis, H&E: Haematoxylin and eosin stain, Sub: subcutaneous layer
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appeared in damaged keratinocytes and in the intercellu-
lar space. An increase in the levels of PKC was observed
in the AD group compared with the Ctrl group. This
elevation was significantly decreased by the oral admin-
istration of Douchi. Significant differences were shown
between all of the groups (p < 0.01). Compared to AD
group, PKC was shown to decrease by 88 % in the DT
group (p < 0.01) (Fig. 3).
Regulation of IL-4 production
Increased Th2 cytokine expression is an important
feature of AD. An increase in IL-4 production was
observed in the AD group compared with the Ctrl
group. The results of immunohistochemical staining
with anti-IL-4 antibodies indicated the appearance of IL-
4-positive reactions in the keratinocytes, lymphocytes
and dermal macrophages. Significant differences were
shown between all of the groups (p < 0.01). Compared
with the AD group, Douchi significantly decreased IL-4
levels (p < 0.01). The DT group showed a 65 % decrease
in IL-4 compared with the AD group (Fig. 3).
Regulation of inflammation mediator
Decrease of mast cell secreted cytokines
Mast cells are tissue-based inflammatory cells. Mast cells
are divided into two types as follows: granulated or
degranulated. The granulated type is more, but the
Fig. 3 Effects of Douchi on the alleviation of skin barrier dysfunction and Th2 differentiation. In Sudan Black B results, more thicker lipid lamella
layer (bright blue) were observed on epidermis in the DT compared with AD. Yellow arrow (↖) indicates lipid lamella. PKC and IL-4 positive
reactions (↖, arrow indicates dark brown) were remarkably decreased in DT compared with AD. Data of PKC and IL-4 was also shown same result
in graph of pixel count. Bar size: 100 μm. Abbreviation; BC: Blood clot
Jung et al. BMC Complementary and Alternative Medicine  (2016) 16:416 Page 6 of 14
degranulated type predominates in the inflammatory
state. The induced degranulation of mast cells under
Th2-dominated conditions plays a key role in inducing
inflammatory skin damage [38].
The results of Luna’s staining indicated that many
degranulated mast cells appeared from the dermal
papilla to the area around the subcutaneous layer in the
AD group. On the other hand, fewer mast cells, which
were primarily granular, appeared in the DT group
compared with the AD group (Fig. 4).
Substance P, which is a neuropeptide related to
ache and itching, causes neurogenic inflammation [39].
Fig. 4 Regulating effects of Douchi on cytokines secretion of mast cell. In Luna’s staining, more granulated mast cells (arrows indicate purple)
were observed in the dermis of DT than in that of AD. Decreased numbers of substance P-positively reacted cells (arrow indicates dark brown)
were observed in the DT compared with the AD. In MMP-9 immunohistochemistry results, MMP-9-positively reacted cells (arrow indicates dark
brown in dermal macrophage) decreased in the DT compared to the AD. In M/T results, collagen fibers (bright blue) decreased in AD compared
with DT. Arrows (↕) indicate hyperplasia of the epithelium. Bar size: 100 μm. *: p < 0.01 compared with AD, #: p < 0.01 compared with Ctrl.
Abbreviations; M/T : Masson’s trichrome staining
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Substance P level was increased in the AD group. The
result of immunohistochemical staining with anti-
substance P antibody indicated that substance P-positive
reactions appeared in keratinocytes and dermal macro-
phages. Significant differences were shown between all
of the groups (p < 0.01). The reactions observed in the
DT group decreased by 61 % compared with those
observed in the AD group (p < 0.01) (Fig. 4).
MMP-9, which is a collagenase, induces tissue destruc-
tion by degrading the proteins that constitutes the extra-
cellular matrix and the basement membrane.
Consequently, MMP-9 causes edema that facilitates the
migration of inflammation-related cells. In the AD
group, MMP-9 production increased. The results of
immunohistochemical staining with anti-MMP-9 anti-
body indicated the appearance of MMP-9-positive
reactions in keratinocytes and dermal macrophages.
Significant differences were shown between all of the
groups (p < 0.01). The reactions observed in the DT
group decreased by 70 % compared with those of the
AD group (p < 0.01) (Fig. 4).
Repeated D. farinae application for 3 weeks induced
severe AD-like skin lesions. The result of Masson’s tri-
chrome staining showed decrease of collagen fiber distri-
bution in the AD group 3 weeks after the induction of
AD-like skin lesions (Fig. 4). We observed skin damage
such as elimination of the stratum corneum, epithelial
cell hyperplasia, increased infiltration of granular leuko-
cytes and lymphocytes into the basal layer, increased
capillary distribution, and increased edema in the
dermis. These are basic histologic patterns of inflamma-
tory skin disease [40]. In contrast, the DT group
exhibited less skin damage in most regions (Fig. 4).
Regulation of inflammatory cytokine
To estimate the Th2 differentiation, we also measured
the level of phosphorylated IκB (p-IκB). NF-κB is a tran-
scription factor which plays an important role in expres-
sion of Th2 cytokines [41], and the facilitated NF-κB
accelerates AD by enhancing the production of inflam-
matory cytokine [42]. Signaling of p-IκB activates trans-
location of NF-kB in cytoplasm [43], so we can know
production of NF-κB through level of p-IκB. The level of
p-IκB increased in lymphocytes and dermal macro-
phages in the AD group compared with the Ctrl group.
The DT group showed a 23 % (p < 0.01) decrease in
p-IκB as compared with AD group (Fig. 5).
iNOS, produces inflammation by vasodilation, which
occurs through the production of nitric oxide, increased
in the AD group. The results of immunohistochemical
staining with anti-iNOS antibodies indicated the appear-
ance of iNOS-positive reactions in dermal macrophages.
Significant differences were shown between all of the
groups (p < 0.01). The DT group showed a 77 % decrease
in iNOS compared with the AD group. There was a
significant difference between the AD and Ctrl groups
(p < 0.01) (Fig. 5). In results of Phloxine-tartrazine stain-
ing, the size and branches of capillary were also in-
creased in AD group compared with DT group (Fig. 5).
Regulation of Th1 differentiation
To estimate the regulation of Th1 differentiation, we
measured the levels of IL-12 and TNF-α positive reac-
tion (Fig. 6). IL-12 induces cell-mediated immunity by
up-regulating Th1 cytokines, and TNF-α is responsible
for promoting Th1 cell differentiation as pro-
inflammatory cytokine in the pathogenesis of chronic in-
flammatory disease [44]. The levels of IL-12 and TNF-α
increased in lymphocyte and dermal macrophages in the
AD group compared with the Ctrl group. The DT group
showed a 82 % (p < 0.01) decrease in IL-12B and TNF-α
as compared with the AD group (Fig. 6).
No side effect
No significant toxicity such as weight change and liver
toxicity was not observed in all groups (Fig. 7). We used
oral single dose of 20 mg/kg of Douchi on basis of previ-
ous study [45]. Moreover, no significant toxicity was
reported in cells or animals treated with soybean related-
product [46, 47] and also was reported that Douchi has no
toxicity under high-dose up to 2.5 g/kg/day [47].
Discussion
In this study, we investigated whether Douchi alleviates
AD-like skin lesions through modulating PKC and IL-4
in NC/Nga mouse model. We have shown that Douchi
decreased the activation of PKC, IL-4 and its down-
stream targets, mast cells; these effects are associated
with decreases in inflammatory mediators such as
substance P, MMP-9, and iNOS. Inhibiting inflammatory
factors also decreased in AD symptoms such as itching,
edema and angiogenesis.
To induce AD-like skin lesion, we used D.farinae anti-
gen in mice. D.farinae was usually used to induce
inflammatory skin lesion in many AD animal experi-
ments [32–35] and which is common house dust mite
allergens and known to be suitable method for preparing
AD-like skin lesions in experimental animal models [48].
Application of D.farinae induced AD-like skin symptoms
in mice. In our results, we confirmed morphological skin
damage and infiltration of inflammatory cells increased
after application of D.farinae.
To identify more detailed skin inflammation of all of the
groups, clinical severity of the skin lesions was scored by
previously described method for human AD [36]. Oral
administration of Douchi alleviated clinical sign such as
erythema, hemorrhage, edema, erosion, excoriation and
scaling. In addition, Douchi also decreased histological
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changes such as elimination of the stratum corneum, epi-
thelial cell hyperplasia, increased infiltration of granular
leukocytes and lymphocytes, increased capillary distribu-
tion and decreased collagen fiber distribution (Fig. 2),
which are characteristics of inflammatory skin disease.
Now we present our detailed analysis on the mech-
anism of the AD improvement as follows. Firstly,
deficiency of ceramides in stratum corneum is an es-
sential etiologic aspect in the early events of AD [49],
where the deficiency of ceramides is represented by
PKC level [50]. As shown in Fig. 3, D.farinae applica-
tion decreased both of ceramide in stratum corneum
and lipid lamella layers, and increased PKC level. In
this regard, we understand that Douchi administration
suppressed damage to lipid lamella, which means that
Douchi alleviated occurrence of AD through reducing
damage to epidermal layers.
Further to damaging the lipid barrier, PKC activates
Th2 cell functioning by regulating PKC-dependent Ca2+
channels [14]. As shown in Fig. 3, both of PKC and IL-4
were increased in AD group. In contrast, the results
showed decreased both PKC level and IL-4 level in DT
group. Therefore, it could be understood that PKC
affects to IL-4 reduction by suppressing Th2 cell
functioning after Douchi administration. The authors
believe that Douchi significantly decreased AD-like
Fig. 5 Effects of Douchi on regulation of inflammatory factors (NF-κB and iNOS). P-IκB positive reaction (↖, arrow indicates dark brown) decreased
in DT compared with AD. iNOS-positively reacted cells (↖, arrow indicates dark brown) decreased in DT compared with AD. The capillary size and
branches (P/T) were more appeared in the AD compared with DT. Bar size: 200 μm. *: p < 0.01 compared with AD, #: p < 0.01 compared with Ctrl.
Abbreviations; P/T: Phloxine-tartrazine staining
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Fig. 6 Effects of Douchi on regulation of Th1 differentiation. IL-12 and TNF- α positive reaction (↖, arrow indicates purple) decreased in DT
compared with AD. Data of IL-12 and TNF- α image analysis were also shown same result in graph of pixel count. Bar size: 100 μm. *: p < 0.01
compared with AD, #: p < 0.01 compared with Ctrl
Fig. 7 Side effect of Douchi administration. In all groups, no significant damage of liver was observed in H&E result. Significant weight change
was also not identified in during the entire experiment in all groups. Bar size: 200 μm. Abbreviations; CV: Central vein, PV: Portal vein, INI: initiation
of experiment, FIN: final period of experiment
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inflammatory symptoms through regulating IL-4 through
suppressing PKC level.
Next, IL-4 promotes release of IgE by B-lymphocyte,
and the elevated IgE binds to the high-affinity IgE recep-
tors (FcεRI) on the mast cells and causes the mast cell
degranulation [51]. This process plays a key role in the
inflammation. From our results such as Figs. 3 and 4, we
identified that Douchi suppressed the IL-4 level and the
mast cell degranulation. Considering the above relation
between the IL-4 promotion and the mast cell degranu-
lation, we understand that our results also show the
same results and suppression of mast cell degranulation
could be induced by IL-4 suppression.
The mast cell degranulation caused by IL-4 promotion
also affects to increase of symptoms of AD such as itch-
ing or edema by releasing inflammatory mediators like
substance P or MMP-9 [52, 53]. In detail, regarding itch
sensation, mast cells are characterized by abundance of
secretory granules that contain numerous preformed in-
flammatory mediators such as histamine, where the
secretory granules are bound to itch-related receptor
[51]. The bind of secretory granules to the itch-related
receptors promotes the release of substance P from the
specific sensory nerves. It is known that substance P is
one of the most potent pruritogenic peptides [54]. In
our results, the mast cell degranulation and the sub-
stance P release were observed (Fig. 4). We believe that
Fig. 4 showed that Douchi could suppress mast cell
degranulation, which led to reduction of the substance P
release, considering the above itch sensation mechanism.
On the other hand, regarding edema in skin, the mast
cell receives stimulatory signals while interacts with
activated IL-4, that serves to influence MMP-9 release.
MMP-9 induces edema by eliminating collagen fibers in
the extracellular matrix, edema is one of characteristics
of inflammation [52].
Taken together, we identified the levels of substance P
and MMP-9 were significantly suppressed in the DT
group when compared with the AD group (Fig. 4).
According to these results, the reduction of the sub-
stance p and MMP-9 by Douchi administration could
contribute to alleviate AD-induced skin edema and
morphological changes, suggesting that treatment with
Douchi can reveal less inflammatory situations in skin
through regulating IL-4.
In addition, the authors believe that there can be other
AD pathway beginning from IL-4 to iNOS. Th2 cytokine
such as IL-4 activates NF-κB through lipopolysaccharide-
induced NF-κB pathway [55], where NF-κB is one of well-
known iNOS inducers [56]. Regarding this type of AD
pathway, we understand Douchi also shows anti-inflam-
matory effect as described below. In our study, suppres-
sion of IL-4 level was observed, as well as suppression of
p-IκB level and iNOS level. Also, our results also showed
improvement in AD symptom like angiogenesis. That is,
IL-4 suppression could be interpreted as reduction of NF-
κB, which causes improvement in suppression of iNOS
level, where suppression of iNOS level is considered as
mitigation of angiogenesis. In sum, PKC and IL-4 are ori-
ginal effectors inducing AD-like skin lesion, and our re-
sults suggests that Douchi reduces infiltration of
degranulated mast cells and inflammatory mediators (sub-
stance P, MMP-9 and iNOS) through suppression of PKC
and IL-4 activity.
To confirm contribution of constituents of Douchi, we
confirmed HPLC analysis. Our HPLC analysis revealed
Douchi contains isoflavones, such as genistein and daid-
zein (Fig. 1). The result coincided with previous study that
the fermented soybean contains isoflavones [57]. Douchi
have more isoflavones including genistein, daidzein, genis-
tin, daidzin than raw soybean (Fig. 1). Previous studies re-
ported that isoflavone inhibits tyrosine kinases, such as
PKC [58], and is known to inhibit iNOS [59]. The most
constituent of Douchi is genistin, so anti-inflammatory ef-
fect of Douchi was considered to be most influenced by
genistin. Genistin is known to inhibit effectively pro-
inflammatory factors such as TNF-α in inflammatory dis-
ease [60]. In addition, genistin and daidzin attenuates col-
lagenase MMP-9 [61]. Therefore, these components were
considered to effect alleviate AD-like symptoms through
the down-regulation of PKC, iNOS, MMP-9 and TNF-α.
Actually, AD is known to be a biphasic inflammatory
skin disorder, provoked by an imbalance between Th1
and Th2 immune responses [44]. So, we identified Th1
cytokine level additionally. To identify Th1/ Th2 imbal-
ance, we measured IL-12 and TNF-α as Th1 markers,
IL-4 and p-IκB as Th2 markers additionally. IL-12 and
TNF- α plays a key role in Th1 differentiation, while IL-
4 and p-IκB is essential for Th2 development. According
to our immunohistochemistry result, both of Th1 (IL-12
and TNF- α) and Th2 marker (IL-4 and p-IκB) were
decreased after Douchi administration. In addition, dam-
age of lipid lamella resulted in increasing Th1 and Th2
cytokines in our results. Although, Th1/Th2 imbalance
is known to be the main characteristic of AD, recently,
many studies also reported that up-regulation of Th1
and Th2 cytokines were observed in AD patients [62,
63], and herbal applications decreased Th1 as well as
Th2 cytokines, which may lead to alleviation of symp-
tom of AD [64, 65]. Likewise, Douchi also suppressed
Th1 and Th2 markers and these results may lead to
improvement of AD.
Fermentation is a popular processing method to
decrease allergenic property of raw soybean and improve
the nutritional properties [66]. By previous study, after
the fermentation of soybeans, the contents of the
secondary physiologically active ingredients are in-
creased, especially isoflavones and free amino acids [66].
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Our results of comparing the components of raw
soybean and Douchi are also identified same as previous
study. It was shown that Douchi have more isoflavones
compared with raw soybean after fermentation. These
finding suggests that isoflavones in raw soybean are
increased through the process of fermentation, this is
considered to affect alleviation of inflammation. Recently,
it was reported that artemisia have an anti-inflammatory
effect in psoriasis animal model [67]. Therefore, in our
result of change through fermentation, anti-inflammatory
effect of Douchi may be associated with artemisia extract.
In traditional medicine, Douchi has known to enhance
heat-clearing effect in skin through fermentation with
artemisia apiacea and mori folium [21], there are not
sufficient evidence at present, so further analysis are
needed about contribution of components.
In traditional medicine, the most common pattern of
AD is heat, when heat predominates in skin, there may
be more redness inflammatory state [17]. Inflammatory
diseases such as AD are considered to be heat-abundant
states of a body [19]. In a previous study, inflammatory
cytokines such as IL-4 were mainly related to the “Hot
Zheng (heat-abundant symptoms)” [19]. Thus, traditional
medicinal techniques consisting of “purging the heat of
the skin” may contribute to suppression of inflammatory
cytokines. Douchi has been known in traditional medicine
to remove heat and other exterior pathogenic factors due
to its ‘cold’ property [21]. In our results, Douchi reduced
inflammatory cytokines, including IL-4. Our results
suggest that the inhibition of inflammatory cytokines is
considered to be a result from one mechanism underlying
the ‘heat-clearing’ effects of Douchi.
We identified inhibition of IL-4 in AD-induced NC/
Nga mice. In infants with Th1/Th2 imbalance, extrinsic
allergen can easily cause Th2-dominant condition that
leads to AD. This is our reason for 3-week-old NC/Nga
mice, in contrast to be used 7 to 8-week-old NC/Nga
mice. These mice are used as a model for children with
immune conditions who are sensitive to extrinsic
allergens [68]. We confirmed that Douchi downregulated
IL-4 and p-IκB (Th2 markers); this demonstrated that
Douchi had possibility of the less AD-inducing effect
through downregulating Th2 cytokines in infants.
In summary, our results demonstrated that Douchi
treatment was effective in attenuating inflammation in
AD-induced NC/Nga mice and that this inhibitory effect
might be associated with the regulation of the immune
response by decreasing Th2 cytokine and PKC activity.
Therefore, this study provides evidence that Douchi
alleviates inflammation in AD-induced mice and might
have potential in the prevention and treatment of AD.
However, we believe that further studies are needed to
clarify the detailed mechanism of PKC and IL-4 inhib-
ition and the role of Th1 cytokines in the mechanism.
Conclusion
We attempted to identify inflammation-alleviating effect
of Douchi in AD-like NC/Nga mice through inhibiting
PKC and IL-4 activation. As these factors are essential
factor of AD, these lead to regulate various inflammatory
mediators. Therefore, this study provides proof that the oral
administration of Douchi inhibits AD-like inflammation
in mice and may have potential for the prevention and
treatment of AD.
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